Evidence map›Paper›PMID 37230763›Full record

Observational studyBMJ open respiratory research2023

Registry-based study in people with cystic fibrosis and an

Mark Higgins, Thalia Farietta, Daniel Campbell, Meng Liu, Josh Ostrenga, Alexander Elbert, Judy Shih, Nataliya Volkova

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mark HigginsVertex Pharmaceuticals Europe Ltd, London, UK Mark_Higgins@vrtx.com.
Thalia FariettaVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Daniel CampbellVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Meng LiuVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Josh OstrengaCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Alexander ElbertCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Judy ShihVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Nataliya VolkovaVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Vertex Pharmaceuticals (United States) · USCystic Fibrosis Foundation · USVertex Pharmaceuticals (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIvacaftor approval was extended to people with cystic fibrosis (CF) and an

methodsKey outcomes were evaluated in ivacaftor-treated people with CF and an

resultsThe ivacaftor cohort included 369 people with CF and an

conclusionsThe results support the clinical effectiveness of ivacaftor in people with CF and an

Indexed as

Cystic FibrosisAdultAminophenolsChildCystic Fibrosis Transmembrane Conductance RegulatorHumansMutationQuinolonesRegistriesAminophenolsCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolonesCystic Fibrosis

Identifiers

PMID37230763
PMCPMC10231020
OpenAlexW4378211674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.